Agios Pharmaceuticals, Inc. · NASDAQ:AGIO
Agios Pharmaceuticals — Merger or Acquisition (December 2020)
23 slides from Agios Pharmaceuticals's merger presentation, Dec 21, 2020
Slide 1: Embracing Our Past, Reimagining Our Future
EMBRACING OUR PAST, REIMAGINING OUR FUTURE December 21, 2020 Exhibit 99.2
Slide 2: Important Information for Investors and Stockholders
Important Information for Investors and Stockholders Additional Information and Where to Find It This communication relates to the proposed transaction involving the sale by Agios Pharmaceuticals, Inc. (“Agios”) of its oncology business to Servier Pharmaceuticals, LLC. In connection with the propose
Slide 3: Forward Looking Statements
Forward Looking Statements Certain statements contained in this communication may constitute forward-looking statements within the meaning of within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchan
Slide 4: As always, we are driven by our sense of urgency to help patients
As always, we are driven by our sense of urgency to help patients. LEARN MORE AT KNOWPKDEFICIENCY.COM
Slide 5: We are at an inflection point
We are at an inflection point For more than a decade, our mission has been to create differentiated, small molecule medicines for patients. Our successes have resulted in a wealth of promise and opportunity. We intend to leverage this position of strength to make the best choices for our future bold
Slide 6: Singularly focusing on genetically defined diseases and positioning oncology for success
By singularly focusing on genetically defined diseases and positioning our oncology portfolio for success with Servier, we can make the greatest impact. To maximize the value and promise of our diverse portfolio, we have made a deliberate choice of where to focus our efforts and investment We had ea
Slide 7: Deal with Servier captures the full value of the oncology portfolio
Today we announce a deal with Servier that captures the full value* of the oncology portfolio to accelerate and expand our efforts in genetically defined diseases As part of the definitive agreement with Servier for the acquisition of the oncology portfolio, Agios will receive: Cash consideration of
Slide 8: Result of a comprehensive strategic review and competitive sale process
These decisions are the result of a comprehensive strategic review of the company’s business and a competitive sale process We conducted a comprehensive strategic review of the company’s assets led by our board of directors and management team, with assistance from independent financial advisors, ai
Slide 9: Profile of the reimagined Agios
Profile of the reimagined Agios will present a compelling investment opportunity Will realign capital structure to reflect stage of maturity based on our genetically defined disease pipeline with a plan to return at least $1.2B of the $1.8B upfront proceeds Remaining proceeds together with current c
Slide 10: Singular focus sets the stage for building long-term value
Mitapivat approvals in 3 initial indications Broad clinical pipeline of at least 5 molecules exploring at least 10 indications Robust research pipeline poised to deliver a new IND every 12-24 months Cash-flow positive Singular focus in genetically defined diseases sets the stage for building long-te
Slide 11: Affirming Our Legacy
AFFIRMING OUR LEGACY Embracing who we are and what we built
Slide 12: Our journey has delivered great successes and an expanded focus
Our journey has delivered great successes and an expanded focus... 2008 Founded Agios to unlock a new field of discovery in cellular metabolism 2009 Published groundbreaking research in Nature, re: role of the IDH1 mutation in cancer genesis 2010 Entered into strategic collaboration with Celgene to
Slide 13: Supported by incredible productivity, from early research to medicines
...supported by incredible productivity, from early research to commercially available medicines 8 70+ 10+ INVESTIGATIONAL NEW DRUG CANDIDATES PEER-REVIEWED PUBLICATIONS RESEARCH PROGRAMS MEDICINES APPROVED PATIENTS TREATED BY OUR MEDICINES ADDITIONAL MOLECULES IN CLINICAL DEVELOPMENT ~6,000 2 4
Slide 14: Accelerating Our Impact
ACCELERATING OUR IMPACT Adapting to preserve and expand the difference we make
Slide 15: Our refocused therapeutic area and differentiated foundational elements
Our refocused therapeutic area is defined by a combination of our most differentiated foundational elements CELLULAR METABOLISM Cellular metabolism is a central part of our heritage and scientific competency GENETICALLY DEFINED DISEASE Genetically defined disease is a broad umbrella that encompasses
Slide 16: We are the pioneering leaders in PKR activation
We are the pioneering leaders in PKR activation STUDYING PKR ACTIVATION IN THE CLINIC A LOT OF FIRSTS: DISEASES WITH POC ACHIEVED + 6 YEARS 1st INTERNATIONAL PK DEFICIENCY ADVOCACY COUNCIL 1st HEMOLYTIC ANEMIA ADVOCACY COALITION BUILDING 1st GLOBAL PK DEFICIENCY REGISTRY ~190 17 JOURNAL ARTICLES PUB
Slide 17: Building a robust mitapivat pipeline across three indications
Early Stage Clinical Late Stage Clinical Regulatory Submission Near-Term Milestones Expected Approval Positive topline data announced in Dec. 2020 2022 Topline data expected in Q1 2021 2022 Finalize pivotal plan in 1H 2021; Initiate pivotal plan in 2021 TBD Finalized pivotal plan in Dec. 2020; Initi
Slide 18: Significant opportunities exist beyond our initial pipeline focus
Significant opportunities exist beyond our initial pipeline focus Mechanism Molecule Approval Stage Pyruvate kinase activation: 20+ potential indications Indications Aminoacidurias/acidemia: 6+ potential indications AG-348 (mitapivat) AG-946 Development candidates Others PKR PKM2 Development candida
Slide 19: Achieving Our Potential
ACHIEVING OUR POTENTIAL Taking action to realize our goals and opportunity
Slide 20: Plan accelerates impact for patients with genetically defined diseases
By finding an excellent home for our oncology business, our plan accelerates and increases the impact we can make for patients with genetically defined diseases With a clear, singular focus on genetically defined diseases, we will have the ability to make a difference for more patients by: Shifting
Slide 21: Agios Tomorrow
AGIOS TOMORROW BY LEVERAGING Culture of continuous development and patient-first orientation Deep understanding of disease biology and expertise in cellular metabolism Emphasis on translational research, starting in early stage discovery Proven success in drug discovery, development and commercializ
Slide 22: Transaction Highlights
Transaction Highlights Definitive agreement with Servier for the acquisition of the oncology portfolio maximizes value of these programs and positions them for success Agios will receive: Cash consideration of up to $2B 5% royalties on U.S. net sales of TIBSOVO 15% royalties on U.S. net sales of vor
Slide 23: Thank You
THANK YOU
Agios Pharmaceuticals — Merger or Acquisition (December 2020) on 6ix